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Ninety-three patients with liver metastases under-
went selective hepatic arterial infusion of chemothera-
peutic agents through a surgically implanted hepatic
artery catheter and pump. Fourteen patients who devel-
oped upper gastrointestinal symptoms at some time
during the course of treatment were found to have
gastroduodenal disease endoscopically. The severity of
symptoms did not necessarily correlate with severity of
endoscopic findings. There was no temporal relation
hetween 5-f1uoro-2'-deoxuridine infusion and symp-
toms; however, with mitomycin C, symptoms worsened
in five of eight patients within 2 wk of the initial
injection. Patients who received mitomycin C had more
severe endoscopic findings and two of the 14 patients
required partial or total gastrectomy. When hiodegrad-
ahle starch microspheres were coadministered with mi-
tomycin C this was not associated with a higher inci-
dence of gastroduodenal disease. The early experience
with therapy using this system has been associated with
a significant incidence of upper gastrointestinal symp-
toms. The presence of gastrointestinal symptoms in
such patients should alert one to potentially serious
disease.
INTRODUCTION
Percutaneous hepatic artery infusion with chemo-
therapeutic agents in patients with hepatic metastases
has been associated with improved clinical responses
and prolonged survival (1-4) compared to controls
given conventional systemic chemotherapy.
However, numerous complications have been de-
scribed in patients treated with percutaneous hepatic
artery catheters (1-11), including arterial thrombosis,
catheter displacement, abdominal pain, gastroduodenal
ulcerations, and upper gastrointestinal bleeding.
In an effort to avoid some of these complications,
catheters placed surgically into the splenic or gastro-
duodenal artery with ligation of vessels supplying the
stomach or pancreas have been used for delivery of
chemotherapeutic agents. This results in perfusion of
both lobes of the liver without flow to the stomach or
pancreas. Restricted hepatic perfusion with chemother-
apeutic agents having a high hepatic extraction ratio
permits delivery of large concentrations while theoreti-
cally reducing systemic toxicity.
Since surgically implanted hepatic artery catheters
have been used only recently, the natural history of
associated gastroduodenal complications has not yet
been described. In our present study, we describe the
spectrum of such complications observed in a group of




Ninety-three of 110 patients who received selective
hepatic arterial infusion of chemotherapy drugs were
followed for more than 2 months. The remaining 17
patients either were lost to follow-up, withdrew volun-
tarily, or died within the first 2 months from cancer
progression. Of the remaining 93 patients, 14 were
referred to the gastrointestinal service for endoscopy.
All 14 patients had persistent midepigastric pain, nau-
sea with vomiting, or evidence of gastrointestinal blood
loss. All patients had taken antacids or cimetidine with-
out relief before endoscopy. Their ages ranged from 38
to 70 yr with a mean age of 60 yr. There were seven
males and seven females. The patients had metastatic
disease to the liver from colon (11 patients), bile ducts
(one patient), breast (one patient), and pancreas (one
patient). Celiac and superior mesenteric angiography
was performed in all patients before laparotomy and
surgical catheter placement. At surgery, the silastic cath-
eter was placed via arteriotomy into the gastroduodenal
artery (nine patients), splenic artery (four patients), or
dorsal pancreatic artery (one patient). In three of these
patients, catheters in two different arteries were re-
quired to assure perfusion of both hepatic lobes. Any
visible branches ofthe hepatic artery not perfusing the
liver were ligated. Before chemotherapy treatment, total
hepatic arterial flow through the infusion catheter was
determined by nuclear angiography with technetium
labeled macro-aggregated albumin (''"TcMAA) (12-
14). All patients received cimetidine and/or antacids
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TABLE 1




























































































































Diffuse gastric erosions, friability, focal hem-
orrhages which worsened in antrum and py-
lorus; duodenal edema and erosion
Diffuse gastric erythema; 2 x 2 cm antral ul-
cer along greater curve; 2 x 2 cm antral
ulcer along posterior wall; pyloric channel
ulcer; unable to enter duodenum
Severe diffuse erosive gastritis
Patchy gastric erythema
Antral ulcerations and severe duodenitis
1.5 X 3.0 cm antral ulcer along lesser curve
extending into pylorus
Erosive duodenitis




Esophagus plus gastric ulcers
Antral erosions, erythema of body
Linear esophageal erosions with friability;
multiple gastric erosions
Diffuse erosive gastritis with ulcerations and
exudates along entire lesser curve; several
discrete erosions along greater curve
immediately after surgery and throughout the treatment
period.
Chemotherapeutic Agents
FUDR and mitomycin C were the two most com-
monly infused drugs. FUDR was given as a protracted
infusion over 2 wk, alternating every 2 wk with normal
saline. Mitomycin C was given either as a 1-min injec-
tion or 30-min infusion. All patients who were followed
for more than 2 months received FUDR and 54 of 93
received mitomycin C. Of the 14 patients who under-
went upper endoscopy, six received FTJDR alone and
eight received FUDR plus mitomycin C. Biodegradable
starch microspheres were coadministered with mito-
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TABLE 2
Patients Receiving Mitomycin
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mycin C in three of 14 patients studied endoscopically,
and in 37 of 93 overall. One patient received three
separate infusions of starch microspheres with mito-
mycin C, one received two infusions, and one received
only one infusion. In a fourth patient, pretesting with
starch microspheres labeled with ''""TcMAA demon-
strated flow to the stomach and spleen, thus micro-
spheres and mitomycin C were not coadministered.
RESULTS
The most common upper gastrointestinal symptoms
were nausea, vomiting, and epigastric pain, which oc-
curred in 13 ofthe 14 patients who were endoscoped
(Table 1). The interval between the initial dose of
chemotherapy and the development of symptoms was
variable, ranging from several days to 9 months. In
addition, the time for initiation of drug therapy to
endoscopy varied from 13 days to 21 months.
The total dose of FUDR infused on an intermittent
schedule in the 14 patients ranged from 375-5500 mg.
Excluding the one patient who received 5500 mg over
19 months, the average cumulative dose of FUDR was
716 mg. One patient, RP, noted symptoms within 4
days of initiating a 2-wk infusion of FUDR (375 mg).
A gastric ulcer was demonstrated endoscopically 2 wk
after infusion of FUDR. The variability in interval
before onset of symptoms may result from the difficulty
of separating them from those commonly associated
with the underlying metastatic disease (Table 1). In no
patients who received FUDR alone were symptoms
immediately worsened after infusion.
Mitomycin C was infused in eight patients. Cumu-
lative doses ranged from 10-60 mg, with an average
dose of 10-30 mg per infusion (Table 2). Five ofthe
eight patients receiving mitomycin C developed symp-
toms within 2 wk of initial injection ofthe drug. Rein-
fusion with mitomycin C was associated with worsening
of symptoms. All of the patients who received micro-
spheres fell into this category. The time interval from
infusion with mitomycin C to endoscopy ranged from
8-90 days.
A number of patients were taking drugs that are
known to be gastric irritants. Four patients were admin-
istered prednisone, which was usually given as an initial
dose of 60 mg, with rapid tapering. One patient was
ingesting aspirin infrequently.
The endoscopic findings are depicted in Table 1.
Gastric lesions were found in all patients and included
patchy gastric erythema, diffuse erosions, and discrete
ulcers. The two most severe cases, CT and SB, showed
diffuse edema, with ulcerations involving the greater
and lesser curves. Erosions and ulcers were seen in the
duodenum in one patient and in the esophagus in
another.
CASE REPORT
CT, a 39-year-old white woman underwent a modi-
fied left radical mastectomy for intraductal breast car-
cinoma. Three of 15 nodes were positive for metastasis.
Breast tumor estrogen receptors were positive. While
receiving systemic chemotherapy with prednisone, liver
metastases were discovered. Because the patient failed
on systemic therapy and because distant metastases
were limited to the liver, a hepatic artery infusion
catheter and pump (via the splenic artery) were sur-
gically implanted and prednisone infusion initiated.
A postoperative nuclear angiographic study with
''"TcMAA showed perfusion of the liver but no other
organs. After two 2-wk courses of FUDR totaling 515
mg shrinkage ofthe liver metastases was observed, but
bone metastases developed. The third treatment con-
sisted of 16 mg of mitomycin C coadministered with
biodegradable starch microspheres infused via the he-
patic artery over a 1-min period. During the last 30 s
of infusion, the patient experienced burning epigastric
discomfort. Because of persistent anorexia, she was
begun on hourly antacids and Cimetidine with meals
and at bedtime. Prednisone dose was tapered to 20 mg
daily. Two weeks later she complained of persistent
nausea, vomiting, and epigastric pain. Repeat liver
spleen scan showed diminution in the size of the liver
metastases. The same dose of mitomycin C and micro-
spheres was infused over a 1-min period with the patient
vomiting at the end of the infusion. Two weeks later a
third dose of mitomycin C was infused. She was admit-
ted to the University Hospital 3 wk later for evaluation
of hematesesis which began 1 day before admission.
Her other symptoms had persisted. Upper endoscopy
revealed marked mucosal edema with erosions, focal
hemorrhages, and fresh blood, predominately in the
gastric fundus, with confluent ulcers and narrowing in
the antrum. Multiple pyloric channel and duodenal
bulb erosions were observed. For the next 4 wk, nausea,
vomiting, and upper gastrointestinal bleeding persisted.
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The patient required 19 U of blood. Upper endoscopy
performed 1 month later showed minimal esophageal
erythema and decreased distensibility ofthe fundus and
body with extensive erosions and ulcerations overlying
necrotic tissue. Despite discontinuing the selective he-
patic chemotherapy, fibrosis and narrowing of the an-
trum had progressed to the point that a GIF-P2 gastro-
scope could not be passed into the duodenum. The
next day she underwent total gastrectomy with esopha-
gojejunostomy. Subsequently, no further gastrointes-
tinal bleeding occurred but the patient died 15 months
later with extensive spinal metastases and sepsis.
DISCUSSION
Most patients treated with hepatic artery infusions
have already failed systemic chemotherapy and thus
have a poor prognosis. However, although no prospec-
tive, randomized study has been reported, response and
survival rates appear to be improved after percutaneous
or surgically implanted hepatic artery infusion chemo-
therapy (1-4, 7). Certain technological advances includ-
ing surgical placement of silastic catheters and reliable
infusion pumps for outpatient treatment make this
mode of therapy more practical. As more physicians
use this treatment, the potential for complications in-
creases. Persistent upper gastrointestinal symptoms
should alert one to potentially severe gastroduodenal
disease.
Fourteen of our 93 patients (15%) were shown to
have gastric or duodenal pathology. Undoubtedly this
number underestimates the prevalence of gastrointes-
tinal pathology since only those patients referred to the
gastroenterology service were evaluated extensively.
The dose and time from initial infusion of FUDR to
symptoms varied tremendously in the 14 patients. In
contrast, symptoms worsened soon after initial infusion
of mitomycin C. In all but one patient endoscopy was
performed within 2 months after treatment with mito-
mycin C, because of worsening symptoms. Since all
patients who received mitomycin C had also previously
received FUDR, it may be the combination of drugs
that is responsible for the pathology. Gastrointestinal
symptoms developing after infusion of chemotherapy
should not be confused with nonspecific systemic ef-
fects of the drug, until gastroduodenal disease is ex-
cluded since they can progress to severe complications
including gastric outlet obstruction or massive hemor-
rhage.
Several possible mechanisms may be responsible for
the development of the gastrointestinal lesions. The
chemotherapeutic agents may be directly toxic to the
gastric cells, causing cell death or alterations ofthe acid
mucosal barrier. Preliminary evidence using tomogra-
phy during hepatic arteriography has shown a small
amount of blood flow to the distal stomach, which was
not seen during HAPS scanning. This is consistent with
the direct toxicity mechanism and explains the predom-
inant antral involvement at endoscopy. Since these
drugs are inhibitors of cell replication, and the gastroin-
testinal mucosa requires rapid cell turnover for main-
tenance ofits integrity, it is possible that the resistance
to injury is markedly diminished. These problems may
be augmented by decreased gastric mucosal blood flow
which may result from ligation of all branches of the
hepatic artery not supplying the liver.
Many clinical studies have been performed using
percutaneous hepatic artery infusion with mitomycin
C, FUDR, or 5-Fluorouracil. Gastrointestinal toxicity
reported in these studies include stomatitis, abdominal
pain, nausea, and vomiting (16, 17). Less attention has
been directed toward defining the cause of the symp-
toms or documenting gastroduodenal disease by endos-
copy or barium studies. Four recent studies have ob-
served gastric or duodenal ulcerations in patients
undergoing percutaneous hepatic artery infusion with
various drugs (1-4). In one study a patient developed
gastric ulceration after accidental perfusion of the left
gastric artery with mitomycin C and FUDR. Massey et
al. (2) described duodenal ulceration in one of 40
patients after infusion with 27 g of 5-Fluorouracil over
21 days. Of 109 patients followed by Reed et al. (3),
five developed gastric or duodenal ulcers during chronic
percutaneous hepatic artery infusion with FUDR, with
two deaths from ulcer perforation. Petrek and Minton
(4) described six cases ofupper gastrointestinal bleeding
(three severe, three mild) in a group of 52 patients
treated with percutaneous hepatic artery infusion with
various chemotherapeutic agents. "Stress" gastritis and
duodenal ulcer disese were found in their patients with
severe disease.
The true incidence of gastroduodenal disease during
hepatic arterial infusion with chemotherapeutic agents
is unknown. Since damage is predominantly mucosal
and the absence of symptoms may not exclude upper
gastrointestinal disease, gastrointestinal endosopy is the
preferred method of evaluation. Currently we are con-
ducting a prospective, controlled trial in patients with
liver metastasis from colon cancer to determine the true
incidence of gastrointestinal lesions in patients under-
going hepatic artery chemotherapy.
Reprint requests: Dr. Timothy T. Nostrant, Division of Gastro-
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